Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Optimer Pharmaceuticals sells its OBI division to Taiwanese investment consortium for $60mm

Executive Summary

Anti-infective drug developer Optimer Pharmaceuticals Inc. has sold its remaining 43.5% ownership in Optimer Biotechnology Inc. (OBI; cancer therapies) to Taiwanese investment consortium Huei Hong Investment for $60mm. OBI will now be a 100% Taiwan-owned company, operating independently.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Buy-out
    • Full Acquisition
    • Payment Includes Cash for Equity

Related Companies